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ruses correlates with progressive CD41 lymphocyte de-*Department of Pathology and Laboratory Medicine
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leading to the T-tropic SI viruses associated with dis-Universite´ Libre de Bruxelles
ease progression (Collman et al., 1992; Shibata et al.,B-1070 Bruxelles
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In order to study the selective pressures that drive the§Department of Pathology
transition from M- to T-tropism, the underlying sourceJames Graham Brown Cancer Center
of permissiveness for M- and T-tropic viruses must beUniversity of Louisville
understood. HIV-1 cell tropism is determined largely atLouisville, Kentucky 40202
the level of virus entry and has been mapped to the
envelope (env) protein, specifically to regions in the
gp120 subunit that include the V3 loop (Cheng-MayerSummary
et al., 1991; Hwang et al., 1991; Kim et al., 1995; Liu
et al., 1990; O’Brien et al., 1990; Shioda et al., 1991;Here, we show that the b-chemokine receptor CKR-5
Westervelt et al., 1991, 1992). In order for HIV-1 to infectserves as a cofactor for M-tropic HIV viruses. Expres-
lymphocytes or macrophages, theenv protein mustbindsion of CKR-5 with CD4 enables nonpermissive cells
to the primary viral receptor, CD4. While CD4 bindingto form syncytia with cells expressing M-tropic, but
results in conformational changes in env (Sattentau andnot T-tropic, HIV-1 env proteins. Expression of CKR-5
Moore, 1991), these are not sufficient to elicit the env-and CD4 enables entry of a M-tropic, but not a
mediated membrane fusion reaction that is a prerequi-T-tropic, virus strain. A dual-tropic primary HIV-1 iso-
site for virus infection. Rather, one or more cofactorslate (89.6) utilizes both Fusin and CKR-5 asentry cofac-
are required in conjunction with CD4 for fusion to occur.tors. Cells expressing the 89.6 env protein form syncy-
The cofactor requirement is most clearly demonstrated
tia with QT6 cells expressing CD4 and either Fusin
by studies showing that expression of human CD4
or CKR-5. The b-chemokine receptors CKR-3 and
(huCD4) in most nonhuman cells (and some human cell
CKR-2b support HIV-1 89.6 env-mediated syncytia for-
lines) fails to make them permissive for virus infectionmation but do not support fusion by any of the T-tropic
or env-mediated syncytia formation (Ashorn et al., 1990;
or M-tropic strains tested. Our results suggest that the
Broder and Berger, 1995; Broder et al., 1993; Chesebro
T-tropic viruses characteristic of disease progression
et al., 1990; Clapham et al., 1991; Dragic et al., 1992,
may evolve from purely M-tropic viruses prevalent 1995; Harrington and Geballe, 1993; Maddon et al.,
early in virus infection through changes in the env 1986). Nonpermissive CD4-positive cells can be made
protein that enable the virus to use multiple entry co- permissive for env-mediated membrane fusion and virus
factors. infection by transient heterokaryon formation with HeLa
cells, indicating that one or more components (or cofac-
Introduction tors) in HeLa cells can, when delivered to nonhuman
cells, render the nonpermissive cells susceptible to
Human immunodeficiency virus type 1 (HIV-1) isolates HIV-1 infection (Broder et al., 1993; Dragic et al., 1992).
exhibit marked differences in their abilities to infect CD4- Recently, a seven-transmembrane domain protein,
positive cells. While all strains infect primary CD41 T termed Fusin, has been shown to serve as a cofactor
lymphocytes, most primary isolates from patients also for T cell–tropic HIV-1 strains (Berson et al., 1996; Feng
infect primary macrophages (M-tropic), are typically et al., 1996). Fusin exhibits approximately 30% homol-
nonsyncytium inducing (NSI), and fail to infect CD41 ogy with members of both the a and b-chemokine recep-
transformed cell lines (Cheng-Mayer et al., 1988). Other tor families, though Fusin has not been shown to bind
isolates replicate well in CD41 cell lines (T-tropic) and chemokines itself (Herzog et al., 1993; Jazin et al., 1993;
are syncytium-inducing (SI) but fail to infect macro- Loetscher et al., 1994; Nomura et al., 1993). Expression
phages. Changes in the biological properties of sequen- of Fusin with huCD4 renders otherwise nonpermissive
tial viral isolates from infected individuals have been cell lines susceptible to env-mediated syncytia forma-
shown to correlate with disease progression.Thus, most tion and virus infection (Berson et al., 1996; Feng et al.,
viruses isolated from individuals shortly after serocon- 1996). However, Fusin does not appear to be utilized as
version and during the asymptomatic phase of infection a cofactor by primary M-tropic NSI virus strains. Be-
exhibit M-tropic NSI phenotypes (Conner and Ho, 1994; cause of the similarity between Fusin and thechemokine
receptors and the fact that the b-chemokines RANTES,Conner et al., 1993; Roos et al., 1992; Schuitemaker et
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MIP-1a, and MIP-1b are the major HIV-1 suppressive and examined for syncytia formation 8 hr after mixing.
As shown in Figure 1, HeLa cells expressing the T cell–factors secreted by CD81 T cells (Cocchi et al., 1995;
Paxton et al., 1996), we examined the ability of several tropic BH8 env protein readily formed syncytia with QT6
cells expressing huCD4 and Fusin but not with cellschemokine receptors to function as cofactors for pri-
maryNSI viruses. We found that the b-chemokine recep- expressing huCD4 and CKR-5. In contrast, HeLa cells
expressing M-tropic env proteins derived from JR-FL ortor CKR-5, which shares 30% amino acid homology with
Fusin and has been shown to bind RANTES, MIP-1a, ADA did not fuse with QT6 cells expressing huCD4 and
Fusin (JR-FL) or fused very inefficiently (ADA). Only smalland MIP-1b (Samson et al., 1996), could function as
such a cofactor; expression of CKR-5 with huCD4 in isolated syncytia were observed with the ADA env pro-
tein (Figure 1). However, syncytia were readily observedotherwise nonpermissive quail and murine cells ren-
dered these cells permissive for syncytia formation me- with M-tropic env proteinswhen huCD4 and CKR-5 were
coexpressed. Fusion was not observed in the absencediated by NSI, but not SI, virus env proteins as well as
for infection by an M-tropic NSI virus. Furthermore, we of CD4 (data not shown) or when a noncleaved fusion-
inactive form of env was used (Figure 1). Identical resultsfound that a dual-tropic primary virus isolate, 89.6, could
efficiently utilize both Fusin and CKR-5 as entry cofac- were obtained when murine PA317 fibroblasts were
used as targets (data not shown), indicating that thetors. In addition, the b-chemokine receptors CKR-3 and
CKR-2b supported syncytia formation mediated by the ability of CKR-5 to support M-tropic env-mediated syn-
cytia formation was not cell type–dependent.89.6 env protein, indicating that at least some primary
virus isolates may utilize an impressive variety of related To examine syncytia formation more rigorously, we
utilized a content-mixing assay (Broder and Berger,entry cofactors. The identification of CKR-5 as an entry
cofactor for M-tropic HIV strains has important implica- 1995; Nussbaum et al., 1994). In this assay, the target
QT6 cells were transfected with plasmids encoding CD4tions for understanding the molecular basis of viral tro-
pism and HIV entry and suggests new possibilities for and either Fusin or CKR-5. In addition, the cells were
infected with vCB21r, a recombinant vaccinia virus thatantiviral strategies. Our finding that HIV-1 89.6 can use
both Fusin and CKR-5 as entry cofactors suggests that expresses b-galactosidase under control of the T7 pro-
moter. HeLa effector cells were infected with recombi-the evolution from a purely M-tropic NSI phenotype to
a T-tropic SI phenotype may result from changes in nant vaccinia viruses that expressed the desired env
protein and with vTF1.1, a recombinant vaccinia virusHIV-1 env that first enable it to use both Fusin and
CKR-5 as cofactors. that expresses the T7 polymerase. Target and effector
cells were infected overnight and then mixed together
and incubated at 378C for 8 hr. If fusion occurs, the
Results cytoplasmic contents of the target and effector cells
mix, leading to b-galactosidase expression (Nussbaum
The b-Chemokine Receptor CKR-5 Functions et al., 1994). Fusion can therefore be monitored morpho-
as a Cofactor for M-Tropic HIV-1 Strains logically by scoring for in situ b-galactosidase activity
We have shown that expression of huCD4 in quail QT6 and biochemically by lysing the cells and measuring
cells, like most other nonhuman cell lines, fails to render b-galactosidase activity, using a quantitative colorimet-
them permissive for HIV-1 infection and env-mediated ric assay (Broder and Berger, 1995; Nussbaum et al.,
syncytia formation. However, syncytia formation medi- 1994).
ated by T cell–tropic (but not M-tropic) env proteins As shown in Figure 2 and quantitated in Figure 3, HeLa
readily occurs when Fusin and huCD4 are coexpressed cells expressing HIV-1 BH8 env protein formed syncytia
in QT6 cells (Berson et al., 1996). Expression of Fusin with QT6 cells transfected with plasmids encoding
and huCD4 also makes otherwise nonpermissive feline, huCD4 and Fusin, but not with cells expressing huCD4
murine, human, mink, and simian cells suitable targets and CKR-5. In contrast, HeLa cells expressing the
for T-tropic env-mediated syncytia formation (Berson et M-tropic JR-FL env protein formed syncytia with QT6
al., 1996; Feng et al., 1996). The QT6 cells were chosen cells expressing huCD4 and CKR-5 but not with cells
for the current study because they can be efficiently expressing huCD4 and Fusin. Fusion was not observed
transfected. when QT6 cells expressed huCD4 alone (data not
The similarity between Fusin and the chemokine re- shown) or with a noncleaved fusion-inactive form of env
ceptors, coupled with the observations that the b-che- (see Figures 2 and 3). Thus, the b-chemokine receptor
mokines RANTES, MIP-1a, and MIP-1b inhibit replica- CKR-5 functions as a cofactor for M-tropic env-medi-
tion of M-tropic HIV-1 strains in CD41 T-cells (Cocchi ated membrane fusion.
et al.,1995; Paxton et al.,1996), prompted us to employ a
syncytia assay to determine if the b-chemokine receptor
CKR-5, which binds RANTES, MIP-1a, and MIP-1b CKR-5 Supports M-Tropic Virus Infection
To determine if expression of CKR-5 and huCD4 could(Samson et al., 1996), could function as a cofactor for
M-tropic HIV-1 isolates. To do this, huCD4 and either render QT6 cells permissive for virus infection as well as
fusion, CD4 and either Fusin or CKR-5 were transientlyFusin or CKR-5 were transiently expressed in QT6 cells.
After 24 hr, the target QT6 cells were mixed with HeLa expressed in QT6 cells. After 24 hr, cells were infected
with the T-tropic HIV-1 strain IIIB or the M-tropic straincells that had been infected with recombinant vaccinia
virus vectors that expressed the env proteins of the JR-FL. The virus inoculum was removed and the cells
harvested 24 hr later. To detect virus entry, we used aT-tropic strain BH8 or the M-tropic strains ADA or JR-
FL. The cells were fixed, stained with methylene blue, polymerase chain reaction (PCR)–based entry assay to
Multiple Entry Cofactors Used by Dual-Tropic HIV-1
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Figure 1. Syncytia Formation Detected by
Methylene Blue Staining
QT6 target cells were infected with vCB3
(moi, 10) expressing CD4 and vCB21r (moi,
10) expressing the lacZ gene under the con-
trol of the T7 promoter. Within 2–4 hr postin-
fection, target cells were transfected with
pSC59–Fusin expressing Fusin from the vac-
cinia synthetic early/late promoter, pCDNA3–
CKR5 expressing CKR5 from the constitutive
CMV promoter, or pCDNA3 vector. HeLa ef-
fector cells were infected with vaccinia (moi,
10) expressing the HIV-1 envelope proteins
BH8, ADA, JR-FL, or a cleavage-defective
form of the BH8 envelope. Effector cells were
also infected with vaccinia vTF1.1 (moi, 10)
expressing T7-polymerase under the control
of the vaccinia late promoter. Cells were al-
lowed to fuse for 8 hr before fixing with glutar-
aldehyde/formaldehyde and staining with
methylene blue.
detect early viral DNA transcripts (Berson et al., 1996). observed when CKR-5 was expressed in place of Fusin.
In contrast, HIV-1 JR-FL entered QT6 cells expressingAs shown in Figure 4, HIV-1 IIIB entered QT6 cells that
expressed both huCD4 and Fusin, consistent with our huCD4 and CKR-5 but not cells expressing huCD4 and
Fusin. Therefore, CKR-5 supported entry of an M-tropicprevious results (Berson et al., 1996). Entry was not
Figure 2. In Situ Detection of Syncytia For-
mation by Cytoplasmic Mixing and b-Galac-
tosidase Expression
Fusion assays were performed using the
same procedure as described in Figure 1, ex-
cept that pREP8–Fusin expressing Fusin from
the Rous sarcoma virus promoter was used
in place of pSC59–Fusin. Cells were allowed
to fuse for 8 hr before fixing in glutaraldehyde/
paraformaldehyde and in situ staining with
b-galactosidase substrate, as described in
Experimental Procedures.
Cell
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Figure 3. Quantitation of Fusion by b-Galactosidase Activity Assay
The fusion assay was performed using the same procedure as de-
scribed in Figure 1. Cells were allowed to fuse for 8 hr before lysis
Figure 4. HIV-1 Infection of CD4-Expressing QT6 Target Cellsin 0.5% NP-40. Cell lysates were harvested and assayed for
b-galactosidase activity, as described in Experimental Procedures. QT6 cells were cotransfected with pT4 and pSC59–Fusin, pCDNA3–
CKR5, or pCDNA3 and then infected with HIV-1 strains BH8, 89.6,
JR-FL, or mock supernatant. The following day, cells were lysed and
HIV reverse-transcription products detected by PCR amplification of
but not a T-tropic virus strain, consistent with its ability U3/U5 sequences, followed by Southern blot. HIV-1 plasmid served
to support membrane fusion mediated by M-tropic env as a positive control. Quail-specific primers were used to demon-
strate that equivalent amounts of DNA were used in each sampleproteins.
(data not shown). The small signal seen with 89.6 infection of QT6
cells expressing huCD4 alone was not reproducible and so most
A Dual-Tropic HIV-1 Strain Utilizes Both likely represents residual virus inoculum; other experiments showed
Fusin and CKR-5 no evidence for virus entry under these conditions.
Most viruses isolated from asymptomatic individuals
replicate in both macrophages and lymphocytes but
do not induce syncytia formation in peripheral blood 5). Syncytia formation did not occur in the absence of
CD4.lymphocytes or in transformed cell lines (Conner and
Ho, 1994; Conner et al., 1993; Schuitemaker et al., 1991, To obtain quantitative fusion data, we again used a
gene reporter assay. Because the recombinant vaccinia1992). With disease progression, more cytopathic
T-tropic SI viruses emerge. Whether cytopathic variants virus that expresses the 89.6 env protein also constitu-
tively expresses b-galactosidase, target QT6 cells wereevolve from M-tropic NSI viruses or emerge from strains
that are suppressed but present during the early stages transfected with a plasmid containing luciferase, rather
than lacZ, under control of the T7 promoter. Using thisof infection is not known. However, viruses with interme-
diate phenotypes have been described, supporting the sensitive assay, we found that HeLa cells expressing
the 89.6 env protein readily fused to QT6 target cellsidea that cytopathic viruses may evolve from noncyto-
pathic strains via a transitional dual-tropic phenotype. expressing huCD4 and Fusin and also to QT6 cells ex-
pressing huCD4 and CKR-5 (see Figure 6A). By contrast,We examined one such dual-tropic virus, 89.6, a primary
virus isolate that retains the ability to replicate efficiently HeLa cells expressing the T-tropic BH8 env protein
formed syncytia only with cells expressing Fusin, whilein macrophages in spite of having SI characteristics and
the ability to replicate in some transformed T cell lines those expressing the M-tropic JR-FL env protein only
fused with cells expressing CKR-5. Finally, we per-(Collman et al., 1992). To determine if the properties of
89.6 could be explained by the ability of 89.6 env to formed the PCR–entry assay to determine if both Fusin
and CKR-5 could support virus entry into QT6 cells inutilize multiple-entry cofactors, we tested the ability of
the 89.6 env protein to fuse with QT6 cells expressing conjunction with huCD4. As shown in Figure 4, we found
that HIV-1 89.6 virus could use both Fusin and CKR-5huCD4 and either Fusin or CKR-5. We found that HeLa
cells expressing the env protein derived from 89.6 failed as entry cofactors, consistent with the membrane fusion
results shown in Figures 5 and 6A. Thus, the dual-tropicto form syncytia with QT6 cells that expressed huCD4
alone, indicating that this dual-tropic virus required one nature of HIV-1 89.6 can be explained by its ability to
use two distinct entry cofactors. A small signal wasor more entry cofactors. In contrast, HeLa cells express-
ing 89.6 env readily formed syncytia with QT6 cells ex- obtained when QT6 cells expressing huCD4 alone were
infected with 89.6 (Figure 4), but this result was notpressing huCD4 and either Fusin or CKR-5 (see Figure
Multiple Entry Cofactors Used by Dual-Tropic HIV-1
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Figure 5. Syncytia Formation by 89.6 env Detected by Methylene Blue Staining
QT6 target cells were transfected with pREP8–Fusin expressing Fusin from the constitutive Rous sarcoma virus promoter, pCDNA3–CKR5
expressing CKR5 from the constitutive CMV promoter, or pCDNA3 vector. All target cells were also transfected with pT4, which constitutively
expresses CD4 from the CMV promoter. HeLa effector cells were infected with vBD3 (moi, 10) expressing the 89.6 envelope. Cells were
allowed to fuse for 8–10 hr before fixing with methanol and staining with methylene blue.
reproducible. Other experiments demonstrated no evi- CKR-2b (which is expressed in monocytes). In addition,
we transfected QT6 cells with a plasmid encoding thedence of 89.6 entry into QT6 cells expressing huCD4
alone (consistent with the syncytia formation assay re- Duffy blood group antigen, a seven-transmembrane re-
ceptor that bears approximately 20% homology to Fusinsults in Figures 3 and Figure 6A), suggesting that this
small signal was due to residual virus inoculum. and has been shown to bind to RANTES, IL-8, and
MCP-1 (Chaudhuri et al., 1994; Neote et al., 1994; Peiper
et al., 1995). Work by Dragic et al. (1995), demonstratingCKR-3 and CKR-2b Support 89.6
env-Mediated Membrane Fusion that fusion of human red blood cell ghosts with murine
cells expressing huCD4 makes these cells susceptibleThe ability of HIV-1 89.6 to use both Fusin and CKR-5
as entry cofactors despite their divergent sequences for syncytia formation mediated by a T-tropic HIV-1 env
protein, suggested that the Duffy antigen might serve(approximately 21% amino acid homology in the extra-
cellular domains) promptedus to examine whether other as a HIV-1 cofactor. In the presence of huCD4, we found
that both CKR-3 and CKR-2b supported syncytia forma-chemokine receptors could function as cofactors for
this dual-tropic virus. QT6 cells were transfected with tion by the 89.6 env protein (Figure 6B), but not by the
BH8 and JR-FL env proteins. The Duffy blood groupplasmids encoding huCD4 as well as the b-chemokine
receptorsCKR-3 (which is expressed in eosinophils) and antigen failed to support membrane fusion by any of
Figure 6. Quantitation of 89.6 Fusion by Lu-
ciferase Assay
(A) QT6 target cells were transfected with
pREP8–Fusin expressing Fusin from the con-
stitutive Rous sarcoma virus promoter,
pCDNA3–CKR5 expressing CKR5 from the
constitutive CMV promoter, or pCDNA3 vec-
tor. All target cells, except where indicated,
were transfected with pT4, which constitu-
tively expresses CD4 from the CMV promoter,
and cells that did not receive CD4 were
transfected with pCDNA3 vector. All target
cells were also transfected with a plasmid
containing the luciferase gene driven by a T7
promoter (Promega). HeLa effector cells were
infected with vBD3 (moi, 10), which expresses
the 89.6 envelope protein, or with viruses that
express the JR-FL or BH8 env proteins. All
effector cells were infected with vTF1.1 (moi,
10), which expresses T7 polymerase under
the control of thevaccinia late promoter.Cells
were allowed to fuse for 6 hr before lysis in
Reporter Lysis Buffer (Promega) and assay
for luciferase activity. Results are expressed
in terms of relative light units (RLU), and raw
data has been multiplied by 1023.
(B) This experimentwas performed in an iden-
tical fashion to that shown in (A), except that
the target cells were transfected with plas-
mids expressing CKR-3, CKR-2b, or the Duffy
blood group antigen.
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the env proteins tested. While the efficiency of fusion cofactor or, as appears to be the case of the M-tropic
strain ADA, is used very inefficiently (Berson et al., 1996;mediated by the different cofactors appeared to vary,
the relative efficiency of Fusin, CKR-5, CKR-3, and CKR- Feng et al., 1996). Given the high degree of homology
between M- and T-tropic env proteins, we speculated2b to support syncytia formation must await develop-
ment of specific antibodies that will allow quantitation that cofactors used by M-tropic viruses would be struc-
turally related to Fusin. The similarity between Fusin andof surface expression levels of these membrane fusion
cofactors. the chemokine receptor families, coupled with recent
work showing that the b-chemokines RANTES, MIP-1a,
and MIP-1b have significant antiviral activity against
Discussion M-tropic but not T-tropic virus strains (Cocchi et al.,
1995; Paxton et al., 1996), made the b-chemokine recep-
HIV-1 isolates can be placed into three groups based tor CKR-5 a likely candidate.
on their ability to infect distinct target cell populations. We found that expression of CKR-5 in conjunction
Viruses that are M-tropic and that fail to form syncytia in with huCD4 in otherwise nonpermissive quail QT6 or
culture represent the most prevalent phenotype isolated murine PA317 cells made these cells suitable targets
from individuals shortly after seroconversion and during for M-tropic env-mediated syncytia formation and also
the asymptomatic period of the disease (Conner and allowed virus entry. It is important to note that CKR-5
Ho, 1994; Conner et al., 1993; Roos et al., 1992; Schui- by itself did not support membrane fusion: fusion was
temaker et al., 1991, 1992; Tersmette et al., 1988, 1989b; only observed when target cells expressed both huCD4
Zho et al., 1993). By contrast, viruses that exhibit a and CKR-5. Expression of huCD4 and CKR-5 did not
T-tropic SI phenotype typically emerge later in infection support fusion or virus entry by the T-tropic strain IIIB.
and are associated with CD41 T cell decline and pro- CKR-5 contains 352 amino acids and has a predicted
gression to AIDS (Tersmette et al., 1988, 1989a, 1989b). molecular mass of 40,600 kDa (Samson et al., 1996). It
Dual-tropic viruses retain the ability to replicate effi- exhibits between 49% and 76% amino acid homology
ciently in macrophages despite exhibiting SI character- with other b-chemokine receptors, being most closely
istics and may represent an important transitional phe- related to CKR-2b. Structural motifs include a single
notype in the evolution of T-tropic SI viruses from the potential N-linked glycosylation site present in the third
M-tropic NSI viruses present early in the course of the extracellular loop and four conserved cysteine residues
disease (Collman et al., 1992; Shibata et al., 1995). An in the ectodomain, with disulfide bonds predicted to
important factor governing cell tropism is the ability of occur between cysteines in the first and second extra-
a virus to enter different target cells. In the case of cellular loops and between the cysteine pair in the
HIV-1, T-tropic viruses generally fail to enter macro- N-terminal domain and third extracellular loop (Samson
phages, while M-tropic viruses often fail to enter trans- et al., 1996; Strader et al., 1994). CKR-5 contains a ser-
formed T cell lines in spite of the fact that both target ine/threonine-rich cytoplasmic domain that is a likely
cells express the primary viral receptor, CD4. Thus, CD4 target for phosphorylation and contains a number of
by itself is not sufficient for virus entry. In addition, ex- conserved proline residues in its transmembrane do-
pression of huCD4 in nonhuman (and some human) cell mains. Functionally, addition of RANTES, MIP-1a, and
lines typically fails to render them permissive for virus MIP-1b to cells expressing CKR-5 induces functional
infection and env-mediated syncytia formation, support- responses, though direct chemokine binding has not
ing the idea that a cofactor in addition to CD4 is required yet been demonstrated (Samson et al., 1996). CKR-5
for HIV-1 entry (Ashorn et al., 1990; Broder and Berger, shares approximately 30% amino acid homology with
1995; Broder et al., 1993; Chesebro et al., 1990; Clapham Fusin, with 38% homology between the transmembrane
et al., 1991; Dragic et al., 1992, 1995; Harrington and domains, 30% between the intracellular loops, and 21%
Geballe, 1993; Maddon et al., 1986). Only recently has between the extracellular domains. The first extracellu-
a bona fide HIV-1 specific cofactor been identified, an lar loop is the most highly conserved ectodomain region,
orphan seven-transmembrane domain receptor termed with 7 of 14 residues being identical between Fusin and
Fusin (Berson et al., 1996; Feng et al., 1996). CKR-5.
Fusin is most closely related to the a- and b-chemo- Viruses representing evolutionary transitions between
kine receptor families (Federsppiel et al., 1993; Herzog T- and M-tropic strains may be unique tools for linking
et al., 1993; Jazin et al., 1993; Loetscher et al., 1994; disease manifestation with the underlying cellular basis
Nomura et al., 1993). However, functional interactions of viral phenotype. The identification of Fusin as a cofac-
between Fusin and various chemokines have not been tor for T-tropic viruses and CKR-5 as a cofactor for
detected (Herzog et al., 1993; Jazin et al., 1993; M-tropic viruses enabled us to determine if the dual-
Loetscher et al., 1994; Nomura et al., 1993). Fusin exhib- tropic nature of 89.6 could be explained by the use
its a broad tissue distribution and is expressed at high of both cofactors. HIV-1 89.6, isolated from peripheral
levels in B-, T-, and monocyte-derived cell lines (Feder- blood mononuclear cells, replicates well in macro-
sppiel et al., 1993; Herzog et al., 1993; Jazin et al., 1993; phages and in peripheral blood lymphocytes (Collman
Loetscher et al., 1994; Nomura et al., 1993). Expression et al., 1992). However, unlike most M-tropic viruses,
of Fusin and huCD4 in otherwise nonpermissive cell infection of peripheral blood lymphocytes with 89.6 re-
lines renders them susceptible to T-tropic env-mediated sults in syncytia formation. In addition, 89.6 can produc-
syncytia formation as well as infection by T-tropic SI tively infect some transformed cell lines, such as
viruses (Berson et al., 1996; Feng et al., 1996). However, CEMX174. We found that despite their divergent se-
quences, both Fusin and CKR-5 supported membraneFusin either is not used by M-tropic NSI viruses as a
Multiple Entry Cofactors Used by Dual-Tropic HIV-1
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fusion mediated by the 89.6 env protein, and both sup- penetration, since expression of huCD4 alone in a non-
permissive cell enables virus to bind but not to fuse withported 89.6 virus entry. The 89.6 env protein has 88%–
the target cell. A series of discrete steps must occur in91% amino acid homology with well-characterized M-
order for HIV-1 to infect a cell. First, the virus must bindand T-tropic viruses but does not exhibit greater homol-
to the surface of the target cell, which generally involvesogy to either group (Collman et al., 1992). The V3 loop
a high affinity interaction between env and CD4. Next,of 89.6, a region of gp120 that has been shown to influ-
a triggering event must elicit a conformational changeence cell tropism, reflects this; it diverges almost equally
in env that leads to membrane coalescence and fusion.from T- and M-tropic viruses. The ability of HIV-1 89.6 to
Only after membrane fusion can the viral capsid enterutilize both CKR-5 and Fusin suggests that thecofactors
the host cell cytoplasm. Therefore, the env protein playsshare conserved conformational features or general
two critical roles in viral entry: receptor binding andstructural characteristics, such as charge, that may be
membrane fusion. While CD4 by itself is sufficient forimportant for cofactor function. The ability of CKR-3 and
binding env, it is not sufficient to trigger the entire seriesCKR-2b to be used as fusion cofactors supports this
of conformational changes in env that are required foridea and suggests that any env–cofactor interactions
fusion tooccur. Fusin and CKR-5may provide the triggerwill be complex in nature. Alternatively, env proteins
that allows fusion to occur. A possible scenario is thatmay harbor distinct sites that govern cofactor usage,
conformational changes in env that result from CD4and 89.6 may possess several such sites. Regardless,
binding could, in turn, allow env to interact with Fusinthe ability of 89.6 to use both Fusin and CKR-5 suggests
or CKR-5, leading to additional conformational changesthat relatively subtle changes in the env protein can
that result in exposure of the fusion peptide and mem-result in the ability to use both entry cofactors. Such
brane fusion. It will be important to test this hypothesisdual tropism could play an important role in the transition
and to determine if env interacts directly with the viralfrom M-tropic NSI to T-tropic SI HIV-1 strains during the
cofactors in either a CD4-dependent or -independentcourse of disease. It will be interesting to determine if
manner. The cofactors may also interact directly withthehigh levels of RANTES, MIP-1a, and MIP-1b secreted
CD4 and perhaps alter its conformation or presentation
by CD41 lymphocytes from someHIV-1 infected individ-
on the cell surface.
uals provide the selective pressure to drive the evolution
The identification of Fusin and CKR5 as entry cofac-
of cofactor usage (Paxton et al., 1996).
tors has important implications for understanding viral
The ability of 89.6 to utilize molecules as divergent as
entry, tropism, and pathogenesis, as well as the genera-
Fusin and CKR-5 as entry cofactors prompted us to tion of transgenic animals that could serve as models
determine if molecules more closely related to CKR-5 for HIV infection. It also opens new areas for potential
could likewise be used by this virus. The b-chemokine therapeutic strategies. The b-chemokines RANTES,
receptors CKR-3 (58% homology to CKR-5) and CKR- MIP-1a, and MIP1-b have significant antiviral activity
2b (76% homology to CKR-5) functioned as fusion co- against M-tropic, but not T-tropic, HIV-1 strains (Cocchi
factors for 89.6 env, while the Duffy blood group antigen et al., 1995; Paxton et al., 1996). The mechanism by
(19% homology) did not. Expression of CKR-3 appears which these chemokines exert their antiviral activity may
tobe restricted toeosinophils (Combadiere et al., 1995b; be through receptor blockade or down-regulation.
Kitaura et al., 1996), making it unlikely that it could serve These or other compounds that prevent cofactor usage
as an HIV-1 cofactor in vivo. However, more detailed may be effective antiviral agents. It will also be important
studies on the distribution of CKR-3, as well as other to determine if other proteins can serve as viral cofac-
chemokine receptors, will be needed. CKR-2b, however, tors. Given the impressive genetic diversity exhibited by
is expressed in monocytes (Combadiere et al., 1995a) HIV-1 strains and the fact that 89.6 can use at least four
and so may be a biologically relevant cofactor for some distinct molecules as fusion cofactors, it will not be
HIV-1 strains. surprising if additional molecules may be able to func-
The finding that fusion of either protease or heat- tion as cofactors for different HIV-1, HIV-2, and simian
treated human red blood cell ghosts with murine cells immunodeficiency virus strains. CKR-5, for example, is
expressing huCD4 rendered these cells competent for more closely related to other b-chemokine receptors
than to Fusin, including CKR-1 (56% homology) whichHIV-1 env-mediated membrane fusion indicated that red
also binds RANTES, MIP-1a, and MIP-1b (Neote et al.,cell membranes contain one or more entry cofactors
1993), and CKR-4 (49% homology) which binds to(Dragic et al., 1992; Puri et al., 1996). We do not yet
RANTES, MIP-1a, and MCP-1 (Power et al., 1995). Theknow if human red cells express any of the known HIV
use of primary virus strains as well as viruses from differ-cofactors, but the presence of the Duffy blood-group
ent clades may reveal additional complexities. Finally,antigen, a promiscuous chemokine receptor, is intrigu-
the ability of 89.6 to use both Fusin and CKR-5 as entrying. However, we found that coexpression of Duffy and
cofactors provides a molecular explanation for its dual-huCD4 in quail cells failed to support syncytia formation
tropic phenotype and provides evidence that evolutionby three different HIV-1 env proteins. While it is possible
of T-tropic SI viruses from M-tropic NSI viruses maythat red cells may contain an as yet unidentified cofac-
involve a transitional phenotype that exhibits a broadertor, it is also possible that processing differences could
range of cofactor usage.account for these observations. The ability of Duffy to
serve as a HIV-1 cofactor could also be tested by re-
Experimental Procedurespeating the experiments of Dragic et al. (1992), using
blood cells from individuals that lack the Duffy antigen. Constructs
Fusin and CKR-5 are likely to play a role in enabling pSC59–Fusin and pREP8–Fusin constructs have been previously
described (Berson et al., 1996). CKR-5 was cloned into pCDNA3the membrane-fusion reaction that is required for viral
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(Invitrogen), using the upstream BamHI and downstream XBAI sites was removed after 4 hr, and the cells were incubated at 378C over-
night. In some experiments, as indicated in the figure legends, CD4for expression using the cytomegalovirus (CMV) promoter. The lucif-
erase–T7 plasmid was obtained from Promega. The plasmid pT4, and T7–b-galactosidase were introduced by infection with recombi-
nant vaccinia viruses at a moi of 10. Cells were infected 2–3 hr priorproviding expression of huCD4 under the control of the CMV pro-
moter, was provided by Dr. Dennis Kolson (University of Pennsylva- to transfection. In infection/transfection experiments, overnight in-
cubation was at 328C in the presence of rifampicin. Transfectionnia). pTLZ, encoding lacZ under the control of the T7 promoter,
was provided by Dr. Chris Broder (National Institute of Allergy and and infection/transfection of target cells yielded identical results,
although infection experiments generally caused cytopathic effectsInfectiousDiseases, National Institutes of Health). The 89.6 envelope
gene was cloned into the vaccinia virus expression vector pSC59 and increased background.
To initiate fusion, target and effector cells were mixed in 24 wellby PCR. Internal regions of the gene were replaced with sequences
not subject to PCR by restriction-fragment swaps, and all areas plates at 378C in the presence of ara-C and rifampicin and allowed
to fuse for 8–10 hr. Syncytia formation was monitored by fixingsubject to PCR were confirmed by sequence analysis. The 59 end
of the clone was defined with PCRprimer TCATTCGTCGACAGATTA the cultures in 0.29% glutaraldehyde/1% formaldehyde/phosphate-
buffered saline and staining with 0.5% methylene blue, 0.17% para-ATTGATA, which introduces a SalI restriction site 46 bp before the
89.6 env start codon. The 39 end of the clone utilizes the natural rosaniline in methanol. To quantitate fusion, NP-40 was added to a
final concentration of 0.5%, and aliquots of the cell lysates wereBspEI site approximately 600 bp after the 89.6 env natural stop
codon. The Sal-to-BspEI sequences were inserted into pSC59 using monitored for b-galactosidase activity using the colorimetric assay
described by Nussbaum et al. (1994). In some cases, b-galactosi-the 59 SalI and 39 Xma sites in pSC59 and a BspEI–Xma linker
sequence previously introduced into the vector. dase was detected by in situ staining. Since the 89.6 env-encoding
vaccinia virus expressed the lacZ gene, quantitation of 89.6 env-
mediated fusion was measured using a luciferase assay. After 8–10Cells
hr of fusion, 2–3 3 105 cells were lysed in 150 ml of reporter lysisThe human cervical carcinoma cell line HeLa was obtained through
buffer (Promega) and assayed for luciferase activity according tothe AIDS Research and Reference Reagent Program (Division of
the instructions of the manufacturer (Promega).AIDS, NIAID, NIH). The murine embryo fibroblast cell line PA317T4
(McKnight et al., 1994) was a gift from Dr. James Simon (University
of Pennsylvania). The Japanese quail fibrosarcoma cell line QT6- Infection Studies
C5 (QT6; ATCC# CRL-1708) was provided by Paul Bates (University pREP8–Fusin or pcDNA3–CKR5 were cotransfected with pT4 (2 mg
of Pennsylvania). HuTK2 143B fibroblasts (#CRL-8303) were ob- of each plasmid) into 2 3 105 QT6 cells in 24 well tissue culture
tained from the American Type Culture Collection. plates, using calcium-phosphate precipitation. The next day, cells
Tissue culture media and supplements were purchased from Life were infected with DNase-treated (15 U/ml for 30 min at room tem-
Technologies, Inc. unless otherwise noted. HeLa, PA317T4, and perature) cell-free virus stock for 4 hr at 378C, using 75 ng p24
HuTK2 were maintained in Dulbecco’s modified Eagle’s media: high antigen each of strains JR-FL, 89.6, or IIIB (derived from clone
glucose, supplemented with 10% fetal bovine serum (Hyclone). QT6 HXB2). Following infection, cells were washed and fed. The cells
cells were maintained in Medium 199, supplemented with 10% tryp- were detached with trypsin 24 hr later, pelleted, suspended in 50
tose phosphate broth (Sigma), 5% fetal bovine serum, and 1% ml lysis buffer (100 mM KCl, 20 mM Tris [pH 8.4], 0.1% NP-40, 500
chicken serum. All media were supplemented with 2 mM glutamine mg/ml proteinase K), and incubated for 2 hr at 608C, followed by
and penicillin–streptomycin. boiling for 15 min.
HIV detection by PCR was performed for 35 cycles on 2.5 ml of
cell lysate to amplify a 430 bp region of U3/U5 LTR DNA sequences,Viruses
using primers LTR-plus/LTR-minus (59-ACAAGCTAGTACCAGTTGADr. Christopher Broder of the NIAID kindly provided us with the
GCC-39; 59-CACACACTACTTGAAGCACTCA-39). Products were re-following panel of recombinant vaccinia viruses encoding the envs
solved by electrophoresis on 2% agarose gels, transferred to Hy-of several HIV-1 strains (indicated in parentheses; Broder and Ber-
bond N1 (Amersham) and probed with a [32P] end-labeledger, 1995): vSC60 (IIIB, BH8 clone), vCB39 (ADA),and vCB28 (JR-FL).
oligonucleotide probe (59-ATCTACAAGGGACTTTCCCGC-39) fol-The recombinant vaccinia virus vCB16, encoding a nonfusogenic
lowed by autoradiography. To ensure that equivalent amounts ofuncleaved BH8 env was used as a negative control. Dr. Broder also
total cellular DNA were amplified, quail cell–specific primers Q101-provided us with the recombinant viruses vCB3 (Broder and Berger,
plus/Q261-minus (5-GGTAACGGTTCTTTGTCCCGTTGC-39; 59-CGC1995), encoding huCD4; vTF1.1, encoding the T7 RNA polymerase;
GCTGGTCCCGCAGCCCCACTC-39) were used to amplify a 153 bpand vCB21r, encoding lacZ under control of the T7 promoter. The
region of the avian sarcoma virus receptor tvA, which is present inrecombinant vaccinia virus vBD3, expressing the 89.6 full-length
QT6 cell genomic DNA (Bates et al., 1993), which was visualized byenvelope protein under control of the vaccinia virus early/late pro-
ethidium bromide staining.moter was generated using standard techniques utilizing thymidine
kinase–negative selection (Earl, 1991). Vaccinia virus was created
by transfecting the pSC59/89.6 gp160 plasmid into CV-1 cells in- Acknowledgments
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